NeurAxis (NASDAQ:NRXS) & ResMed (NYSE:RMD) Critical Review

ResMed (NYSE:RMD – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Risk and Volatility

ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Insider & Institutional Ownership

55.0% of ResMed shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 0.6% of ResMed shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares ResMed and NeurAxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ResMed 27.79% 26.42% 19.43%
NeurAxis -492.76% N/A -641.25%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ResMed and NeurAxis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed 0 10 8 0 2.44
NeurAxis 0 1 1 0 2.50

ResMed presently has a consensus price target of $253.69, suggesting a potential upside of 7.60%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 208.06%. Given NeurAxis’ stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than ResMed.

Earnings & Valuation

This table compares ResMed and NeurAxis”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ResMed $5.65 billion 5.87 $1.52 billion $10.98 21.47
NeurAxis $6.53 million 6.88 -$14.63 million ($1.06) -3.98

ResMed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

ResMed beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About ResMed

(Get Free Report)

ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.